Reset filters
Publication Types
28 October 2021

Joint symposium with the ISHLT: End-stage PAH - how and what do we do in 2021?

  • When should a PH patient be considered for lung transplant? John Granton 
  • Atrial septum defect creation or mechanical support for end-stage PAH Erika Rosenzweig 
  • Lung and Heart-lung Transplant in 2021 – how well do PAH patients do? Eugene Golts
  • Pluripotent stem cell-based approaches and the future of artificial lungs Ulrich Martin
  • Timing and extent of ventricular reverse remodelling after lung transplant for PH Ryan Tedford 
PVRI Digital Webinar Series
30 September 2021

Beyond DNA: The unseen genome and novel omics approaches to PH

  • MicroRNAs and IncRNAs in right heart hypertrophy and failure Francois Potus
  • LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view Stephen Chen 
  • Epigenomics in pulmonary vascular remodelling Soni Savai-Pullamsetti 
  • Multiomic tools for single cell analysis Herbert Schiller
  • Proteomics: From discovery research toward the clinic - novel AI perspectives? Christopher Rhodes 
PVRI Digital Webinar Series
26 August 2021

The notch receptors: multi-regulators of PAH development

  • Role of notch1 in experimental pulmonary hypertension Ralph Schermuly
  • Notch-BMPR interactions in endothelium in PAH Marlene Rabinovitch
  • Notch3 is a driver and biomarker for PAH Patricia Thistlethwaite 
  • Notch3 lineage and pulmonary vasculopathy Maya Kumar 
PVRI Digital Webinar Series
29 July 2021

Pro-Con debate session 1

  • A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH, Peter Dorfmüller
  • Remnants of lost pulmonary vasculature may be re-engaged in PAH, Duncan Stewart
  • Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs, David Systrom
  • Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs, Roham Zamanian
PVRI Digital Webinar Series
24 June 2021

Joint Symposium with the ESC: The pulmonary circulation in the heart failure syndrome

  • The right ventricle in HFpEF, Marco Guazzi
  • Genetic aspects in group2 PH, Mark Toshner 
  • Exercise haemodynamics in heart failure: what can we learn from invasive CPET? Gabor Kovacs 
  • Systemic consequences and interorgan cross-talk in heart failure and PH, Stephan Rosenkranz
  • The natriuretic peptide Clearance receptor selectively causes right ventricular dysfunction in a model of pulmonary hypertension and heart failure with preserved ejection fraction, Vineet Agrawal 
  • N-Lysine methyltransferase Smyd2-mediated HIF-1A stabilization plays a protective role in RV hypertrophy, Swathi Veeroju
PVRI Digital Webinar Series
27 May 2021

Novel imaging approaches in pulmonary hypertension patients

  • Update from the Fleischner Society Task Force for imaging in pulmonary hypertension, Martine Rémy-Jardin
  • Molecular imaging of pulmonary vascular disease using microvascular endothelial cell ligands, Jocelyn Dupuis
  • MRI to assess pulmonary vascular changes and PH progression, Jens Vogel-Claussen
  • Xenon magnetic resonance imaging signatures of PH, Sudarshan Rajagopal 
  • Synchrotron-based phase contrast micro-CT imaging of pulmonary vascular disease in human tissue and animal models, Karin Tran-Lundmark 
PVRI Digital Webinar Series
4 May 2021

Virtual poster discussion session one

  • Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin, Iona Cuthbertson
  • Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension, Prakash Chelladurai
  • Implication of the histone methyltransferase “g9a” in pulmonary arterial hypertension, Charifa Awada 
  • Perinatal exposure to serotonin re-uptake inhibitor causes mild pulmonary hypertension in adult female rats, Barbora Kaftanová 
  • Endothelial overexpression of sirt3 protects the metabolic etiology in PAH, Anandharajan Rathinasabapath
  • Axl is a novel modulator of bone morphogenetic protein receptor 2 in pulmonary arterial hypertension, Tatyana Novoyatleva 
  • Equivalent outcomes for hereditary and idiopathic pulmonary arterial hypertension in children; an analysis from a national Australian registry, Katherine Kearney Graham 
  • Effect of macitentan across prognostic age groups in patients with pulmonary arterial hypertension (PAH), Richard Channick
  • Validation of artificial intelligence artery-vein Classification for Contrast CT imaging in PH subjects, Pietro Nardelli
  • Efficacy in patient subgroups in the INCREASE Trial, a phase III Trial to evaluate inhaled Treprostinil in patients with pulmonary hypertension due to parenchymal Lung Disease, Victor Tapson
  • Acetazolamide and high altitude pulmonary edema prevention, Erik Swenson 
  • Telomeric Tankyrases: a novel and propitious target to ameliorate the maladaptation phenomena at heights, Manjula Miglani 
PVRI Digital Webinar Series
25 March 2021

Connection between COVID-19 and pulmonary vascular disease

  • SARS-1, MERS, SARS-2 and more: are coronavirus infections an ubiquitous part of our lives? Albert Osterhaus
  • Endothelitis and aberrant angiogenesis – mechanisms of COVID-19 induced vascular injury, Danny Jonigk
  • Venous thromboembolism in COVID-19: Prevalence and clinical picture, Stavros Konstantinides
  • ACE-II receptors – Modulation of PVD in COVID-19? Anna Hemnes
  • Tricuspid regurgitation, as proxy for acute pulmonary hypertension, and its association with short-term outcome in severe Covid-19, Claes Frostell 
  • Venous and arterial thromboembolism in COVID-19: a systematic review with meta-analysis, Vicky Mai
PVRI Digital Webinar Series
25 February 2021

Keynote lecture session 2021

  • Health and wearables: Is this the dawn of a new age for cardiovascular medicine? Martin Cowie
  • Professor Sheila Glennis Haworth Memorial Lecture - Translational Research on PAH, Jason Yuan 
  • Biomarker Analysis of the PULSAR Study: An Ongoing Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of PAH, Marc Humbert
  • Switching from PDE5i to riociguat in patients with PAH: The REPLACE study, Raymond Benza
  • A diagnostic miRNA signature for PAH using a consensus machine learning approach (Rupert Swift Award 2021), Niamh Errington
PVRI Digital Webinar Series
11 February 2021

Around the globe: the global burden of pulmonary hypertension

  • The view of the World Heart Federation (WHF), Fausto Pinto
  • Update on the Global Burden of PH Project of the Institute for Health Metrics and Evaluation (IHME), Sophia Emmons-Bell
  • PVRI GoDeep: Perspectives of a global meta-registry, Werner Seeger
  • Mortality of idiopathic/hereditary and connective tissue disease-associated pulmonary arterial hypertension: the data from first single center prospective registry in Indonesia, Anggoro Budi Hartopo
  • Triple therapy in pulmonary arterial hypertension in an expert centre in Mexico City. Real-life results, Humberto Garcia-Aguilar
PVRI Digital Webinar Series